Koesten, Hirschmann & Crabtree, Inc. Compugen LTD Transaction History
Koesten, Hirschmann & Crabtree, Inc.
- $174 Million
- Q4 2024
A detailed history of Koesten, Hirschmann & Crabtree, Inc. transactions in Compugen LTD stock. As of the latest transaction made, Koesten, Hirschmann & Crabtree, Inc. holds 100 shares of CGEN stock, worth $225. This represents 0.0% of its overall portfolio holdings.
Number of Shares
100Holding current value
$225% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding CGEN
# of Institutions
80Shares Held
13.4MCall Options Held
44.9KPut Options Held
8.1K-
Silverarc Capital Management, LLC1.62MShares$3.65 Million0.6% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny1.28MShares$2.87 Million0.0% of portfolio
-
Taylor Frigon Capital Management LLC1.09MShares$2.46 Million0.85% of portfolio
-
Macquarie Group LTD Australia, C31.02MShares$2.3 Million0.0% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD990KShares$2.23 Million0.06% of portfolio
About COMPUGEN LTD
- Ticker CGEN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 86,624,600
- Market Cap $195M
- Description
- Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tu...